Eli Lilly and Co (LSE:LEL) Construction In Progress : $0 Mil (As of Mar. 2024)

View and export this data going back to . Start your Free Trial

What is Eli Lilly and Co Construction In Progress?

Eli Lilly and Co's quarterly construction in progress increased from Sep. 2023 ($0 Mil) to Dec. 2023 ($5,084 Mil) but then declined from Dec. 2023 ($5,084 Mil) to Mar. 2024 ($0 Mil).

Eli Lilly and Co's annual construction in progress increased from Dec. 2021 ($2,178 Mil) to Dec. 2022 ($2,799 Mil) and increased from Dec. 2022 ($2,799 Mil) to Dec. 2023 ($5,084 Mil).

Eli Lilly and Co Construction In Progress Historical Data

The historical data trend for Eli Lilly and Co's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eli Lilly and Co Construction In Progress Chart

Eli Lilly and Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Construction In Progress

Get a 7-Day Free Trial

1,884.40

2,138.80

2,177.80

2,798.60

5,084.10

Eli Lilly and Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Construction In Progress	Get a 7-Day Free Trial															-	-	-	5,084.10	-

Eli Lilly and Co Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

Eli Lilly and Co (LSE:LEL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Eli Lilly and Co (LSE:LEL) » Definitions » Construction In Progress

Comparable Companies

Traded in Other Exchanges

LLY:USA LLY:Mexico 1LLY:Italy LLY:Germany LLY:Switzerland LLY:Canada LILY34:Brazil LLYC:Austria LLY:Argentina

Address

Lilly Corporate Center, Indianapolis, IN, USA, 46285

Website

https://www.lilly.com

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.

Eli Lilly and Co (LSE:LEL) Headlines

No Headlines